CQDMO Services

To resolve the core technical issues of cellular therapy and accelerate the industrialization efficiency of medicine from the source, Hillgene independently researched and developed a serial of technical platforms for cellular therapy, including industrialization of nucleic acid (plasmid/mRNA), HiLenti®-T lentiviral vector system, HiLenti®-NK lentiviral vector system, HiLenti®-serum-free suspension culturing of lentiviral vectors, HiCellx®-completely closed process development for cellular products, and HiCellx® Stem-large-scale production of stem cells. With these independently developed technical platforms, we can offer our clients one-stop CDMO services for cellular therapy, thereby contributing to making more products to the next milestone sooner and faster.